Abstract: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Abstract: Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.

Abstract: It is an object of the present invention to provide a pharmaceutical composition, which can suppress a reduction in the content of an active ingredient caused by oxidation or decomposition of rapamycin or a derivative thereof, can ensure long-term stability, and has high safety. In the present invention, the inventors have found that a tocopherol derivative and an ascorbic acid fatty acid ester are used in combination in a pharmaceutical formulation comprising rapamycin or a derivative thereof, so that oxidation or decomposition of the rapamycin or a derivative thereof can be suppressed, thereby completing the present invention. The rapamycin or a derivative thereof, and the tocopherol derivative and the ascorbic acid fatty acid ester are preferably in the form of a solid mixture produced by preparing a solution containing these components and then removing the solvent from the solution.

Abstract: Disclosed herein is a use of a composition, comprising a non-toxic polyanionic material or a salt thereof to dissociate a polymeric membrane. In addition, a method of dissociating a polymeric membrane is also presented, the method comprising the steps of providing a polymeric membrane; and dissociating the polymeric membrane by adding a composition comprising a non-toxic polyanionic material to the polymeric membrane.

Abstract: Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.

Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

Abstract: One aspect of the present invention is directed to conjugates that comprise a linear polymer carrier, a linker and one or more drugs or imaging agents, as well as pharmaceutical compositions that include such conjugates. The drug may be a platinum-containing drug with a linker comprised of a modified amino acid. The conjugate may alternatively include a metal complexing ligand with a metal used for imaging or chemotherapeutic purposes. Another aspect of the invention is directed to formulations and processes for lyophilization of hyaluronan conjugates. Another aspect of the invention is directed to methods for treating and/or inhibiting cancer utilizing the conjugates and compositions described herein.

Abstract: The present invention harnesses the differential expression of membrane-type matrix metalloproteinases (MT-MMPs) between human solid tumours and normal tissues to provide a systemically inactive prodrug which is selectively activated at the tumour micro-environment. The present invention provides a prodrug which is a conjugate of a taxane and a selective MT-MMP cleavable delivery vehicle.

Abstract: Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.

Abstract: The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin).

Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.

Abstract: The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The disclosure provides improved pharmacokinetics for peptide and small molecule drugs. In some aspects, the disclosure provides a sustained release pharmaceutical formulation. The formulation includes a therapeutic agent for systemic administration, where the therapeutic agent includes an active agent and an amino acid sequence capable of forming a reversible matrix at the body temperature of a subject.

Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.

Abstract: Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.

Abstract: Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.

Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.

Abstract: Provided herein are genetically engineered bacteria that are native to a host insect microbiome. Further provided are methods of inducing RNA interference in an insect, such as a bee, by administering the genetically engineered bacteria.

Abstract: An ultrasound gel is provided for use with internal ultrasound imaging and/or therapy. The gel can have acoustic properties that can closely match a soft tissue to be imaged/treated and can be of a high viscosity that is maintained at body temperature. In some embodiments, the gel can act as a lubricant and, although water based, can be hydrophobic and not dissolve in bodily fluids. In some embodiments, the gel can be sterile, safe for ingestion, safe for application over mucous membranes, and include a preservative. In order to achieve sterility while maintaining a desired viscosity range, the gel can include a viscosity stabilising agent such as a viscosity protection agent for protection from radiation induced breakdown. In some embodiments, methods of altering or maintaining the viscosity of a gel is provided.

Abstract: The present invention provides a method for the purification of 227Th from a mixture comprising 227Th and 223Ra, said method comprising: i) preparing a first solution comprising a mixture of 227Th and 223Ra ions dissolved in an aqueous solution of first mineral acid; ii) loading said first solution onto a strong base anion exchange resin; iii) eluting 223Ra from said strong base anion exchange resin using a second mineral acid in an aqueous solution; iv) optionally rinsing said strong base anion exchange resin using a first aqueous medium; v) eluting 227Th from said strong base anion exchange resin using a third mineral acid in an aqueous solution whereby to generate a second solution comprising 227Th. The invention further provides a purified 227Th solution, a corresponding pharmaceutical formulation and methods of treatment of neoplastic disease.

Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.

Abstract: There is provided a positron-emitting 18F-labelled Factor VII for non-invasive PET imaging of tumor TF expression in humans. More specifically the invention relates to human TFPET imaging of pancreatic cancer metastasis for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

Abstract: A method for removing microorganisms from liquid samples and a nanofiber containing liquid filtration medium that simultaneously exhibits high liquid permeability and high microorganism retention. Microorganisms such as bacteria, particularly B. Diminuta, are removed from a liquid by passing the liquid through a porous nanofiber containing filtration medium having a B. Diminuta LRV greater than about 9, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. Another method for removing microorganisms such as bacteria and Mycloplasma, includes passing the liquid through a porous nanofiber containing filtration medium having a microorganism LRV greater than about 8, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. The filtration medium can be in the form of a fibrous electro spun polymeric nanofiber liquid filtration medium mat.

Abstract: The present invention provides a sterilized-liquefied gas producing apparatus including: a liquefied gas reservoir; a source-gas supplier that supplies a source gas to the liquefied gas reservoir; a cooler that cools down an inside of the liquefied gas reservoir to liquefy the source gas; a supply pipe that connects the source-gas supplier and the liquefied gas reservoir; a sterilization filter provided at the supply pipe; a sterilizer that heats and sterilizes a sterilization region by high-temperature saturated water vapor, the sterilization region being located further downstream than the sterilization filter; and a dryer that removes moisture generated by the heat sterilization to dry the sterilization region.

Abstract: An internal surface electron beam-irradiating device sterilizes the internal surface of a vial by irradiation with an electron beam. The internal surface electron beam-irradiating device includes an electron beam generator that generates the electron beam, a vacuum chamber containing the electron beam generator, an output window that emits the electron beam to the outside of the vacuum chamber, and an extension nozzle that guides an electron cloud formed by extending the electron beam emitted from the output window. The extension nozzle includes a leaking section that leaks the electron cloud. The leaking section includes empty portions that discharge part of the electron cloud to the outside, and a component portion that guides the electron cloud into the leaking section.

Abstract: A computing device in a vehicle can be programmed to activate a self-cleaning glass surface by irradiating the self-cleaning glass surface with LED ultraviolet radiation based on a determined energy of external ultraviolet radiation and a schedule. The computing device can activate a self-cleaning glass surface by irradiating the self-cleaning glass surface with LED ultraviolet radiation based on determining an optical state of the self-cleaning glass.

Abstract: An apparatus for generating an activated sterilization solution is disclosed. The apparatus may include a plasma treatment unit for performing plasma discharge treatment on a gas, and a sterilization solution treatment unit for changing a sterilization solution into a droplet or mist state. The gas treated by the plasma discharge treatment may be mixed with the sterilization solution in the droplet or mist state.

Abstract: A sealable decontamination holding vessel configured to isolate contaminated items being held therein until safe opening of the vessel occurs during a high pressure and temperature sterilization cycle in an autoclave. The vessel basically includes an outer container, a perforated inner receptacle, containment bag and cover lid. The inner receptacle fits into the outer container. The containment bag fits within the inner receptacle with an open end of the bag draped over an open top lip of the inner receptacle. The cover lid is secured and sealed over the open top of the outer container. Patches of self-adhering sealing materials are placed over vent holes in the outer container and cover lid so as to seal the same until they unseal in response to contact with sterilizing steam in the autoclave allowing flow of the steam through the outer container into the inner receptacle and containment bag.

Abstract: A diffuser includes a base, a fan mounted to the base, a receptacle provided over the fan and mounted to the base, a sleeve mounted on the upper surface of the base and enclosing the fan and receptacle, and a lid mounted over the sleeve. Each of the base and the lid comprises at least one opening formed about a periphery thereof. The receptacle comprises a bottom wall with a plurality of opening formed therethrough and a vertically extending sidewall to retain a fragrant medium therein. The fan forces airflow from an exterior of the diffuser, into the base through the at least one opening, through the plurality of openings formed in the bottom wall of the receptacle, through the receptacle and about any fragrant medium therein, into a volume of space above the receptacle enclosed by the lid, and out through the at least one opening in the lid.

Abstract: A fragrance delivery system which includes a container with reservoir compartment and having an outer wall at least partially formed of a fragrance permeable plastic, the plastic being a thermoplastic elastomer block copolymer having a Volume Resistivity from 1×1012 to 1×1020 Ohms·cm and a Water Absorption from 4 to 20%; and a fragrance composition held within the reservoir, the composition being a mixture of low and high volatile perfume ingredients.

Abstract: Disclosed embodiments relate to a virus shield, which for example might be used with a mask worn to protect a user. The virus shield mask might include a container having a UV light source configured to effectively eliminate viruses, thereby allowing for effective virus protection for the user without traditional bulky virus filters. Disclosed embodiments may also include safety features to prevent unwanted or harmful UV exposure.

Abstract: Disclosed is a device including a substrate and a gel layer made of a hydrophilic polymer having a hydroxyl group. The gel layer is fixed to at least a part on a surface of the substrate in a thickness of 1 nm to 3,000 nm and an elastic modulus of a device surface is 6.00×103 Pa or less.

Abstract: The present invention relates to novel and secure tampons that overcome the problems associated with conventional non-secure tampons, and methods of using the novel and secure tampons.

Abstract: Provided are a method of manufacturing a hyaluronate-coated high-functional suture and a high-functional suture manufactured thereby, and more particularly to a method of manufacturing a high-functional suture and a high-functional suture manufactured thereby, wherein a suture for internal and external surgery derived from a conventional chemical synthetic material is coated with a hyaluronate as a biocompatible material, thus improving biocompatibility, functionality and ease of use.

Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Abstract: Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid; hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes.

Abstract: The present disclosure relates to a semipermeable membrane. The present disclosure aims to provide a semipermeable membrane having tolerance against a decrease over time in substance permeability. The present disclosure provides a semipermeable membrane containing a resin. The permeation rate of albumin in the semipermeable membrane is no lower than 30%. The albumin adsorption amount obtained when the semipermeable membrane measuring 1 cm on each side is immersed in a 0.1% albumin solution for 90 minutes is no greater than 10 ?g/cm2. The water permeation amount obtained when water is sucked through the semipermeable membrane at a negative pressure of 3±0.2 kPa is expressed by no smaller than 1,000 L/(m2·hour). The semipermeable membrane can isolate a cell from an external environment.

Abstract: Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Abstract: In general, the present invention is related to biopolymer and biocomposite materials and structures, and methods of making and using the same. In some embodiments, the present invention is directed to oriented collagen based biocomposite materials and structures, and methods of making.

Abstract: The present invention provides a method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel. The injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits superior biocompatibility through addition of TEMPO-oxidized cellulose nanofibers, and excellent cell proliferation and bone regeneration through cellular interaction, and is gelled in vivo, thus being highly useful as a filler for wound healing and bone regeneration. In addition, the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits excellent porosity, has an interconnected structure and is thermogelling, based on thermosensitivity of undergoing a sol-gel transition depending on temperature, thus inducing rapid gelation in vivo and facilitating bone regeneration upon implantation in vivo.

Abstract: The present invention relates to a construct for preventing immunological rejection when used in transplant, whether xenotransplant or allotransplant, which comprises: a) cells with regenerative capacity; b) collagen in 3-D gel state, or also called collagen 3-D matrix, obtained from pig's head cheeks; c) culture medium; d) an element aimed to be transplanted; and e) dry lyophilized spongy collagen molded with the shape of the element to be transplanted; It also relates to a method for producing collagen in a gel state in the form of dry lyophilized spongy mold and 3-D matrix.

Abstract: Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.

Abstract: The present invention relates to a method for preparing an injectable extracellular matrix-based hydrogel. The injectable extracellular matrix-based hydrogel exhibits excellent biocompatibility, and superior cellular proliferation and bone regeneration via intercellular interaction, thus being effectively useful as a filler for bone regeneration. In addition, the injectable extracellular matrix-based hydrogel exhibits excellent porosity, has an interconnected structure and is thermogelling, based on thermosensitivity of showing a sol-gel transition depending on temperature, thus undergoing rapid gelation upon implantation in vivo and promoting bone regeneration.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate and sheet structures.

Abstract: Apparatuses and methods for producing enriched fibrillated tissue matrices are disclosed herein. Some embodiments include a method including subjecting tissue in a carrier liquid to a fibrillation pressure while maintaining a temperature of the tissue and the carrier liquid to at or below a safe zone temperature; inducing a phasic shift and rapid release of water and biological components from the tissue through a disruptive boil and tissue explosion process to produce a fibrillated tissue matrix; and recapturing the water and biological components.

Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.

Abstract: A material comprising an ionically conducting polymer (ICP) positioned between and in direct contact with two electronically conducting polymers (ECP).

Abstract: Vascular scaffolds and methods of fabricating the same are disclosed for tissue engineering of vascular constructs. By combining electrospun matrices with cell sheet technologies, vascular constructs with more mature cell layers can be obtained for reconstruction of blood vessels, heart valves and the like. A engineered smooth muscle cell sheet, wrapped around an electrospun vascular scaffold, is able to provide a mature SMC layer that expresses strong cell-to-cell junction markers and contractile proteins. In addition, preconditioning of the cell sheet covered vascular scaffold maintained cell viability and infiltration into the scaffold.

Abstract: Provided is a gel material for ophthalmic treatment useful as a synthetic vitreous body which is a novel intraocular tamponade material having a low swelling pressure, an appropriate elastic force, and no toxicity to ocular tissues, specifically, to retinas, and which is capable of stably maintaining a long-term stable tamponade effect. A gel material for ophthalmic treatment including a hydrogel in which a gel precursor cluster crosslinks to form a three-dimensional network. The gel precursor cluster has a structure with crosslinked monomer units or crosslinked polymer units present at concentrations less than a critical gelation concentration, and the gel precursor cluster has a relationship of G?<G? where G? represents a storage elastic modulus and G? represents a loss elastic modulus. The hydrogel has a polymer content of 50 g/L or less, a storage elastic modulus G? of 1 to 10,000 Pa at a frequency of 1 Hz, and a fractal dimension of 1.5 to 2.5.

Abstract: The present invention relates a composition for producing a foley catheter which is inserted in vivo and a method for producing the same, which the composition consists of the materials which carbon nanotube polymer (CNT Polymer) bonded a carbon nanotube and zinc oxide (ZnO) is combined with a silicon, wherein from 1.0 to 2.2 parts by weight of the said carbon nanotube polymer are combined with 100 parts by weight of silicon.